Dr Reddys Laboratories posts Q1 FY25 consolidated PAT at Rs. 1,392 Cr
Dr. Reddy's Laboratories has reported total income of Rs. 7,672.7 crores during the period ended June 30, 2024
Dr. Reddy's Laboratories has reported total income of Rs. 7,672.7 crores during the period ended June 30, 2024
The state-of-the-art facility is equipped with best-in-class equipment and control systems
Aurigene.AI is an end-to-end solution for small molecule drug discovery
Under the arrangement, Dr. Reddy's will have exclusive rights to promote and distribute Sanofi's vaccine brands Hexaxim, Pentaxim, Tetraxim, Menactra, FluQuadri, Adacel and Avaxim 80U
Mungara has over 25+ years of experience in the supply chain domain
Dr Reddy’s Laboratories recorded revenue of Rs 6,880.20 crore during the quarter
The USFDA inspectors issued the observations after a product pre-approval inspection of the biologics facility in Bachupally
Subscribe To Our Newsletter & Stay Updated